BCR 164.97 C.R. Bard $BCR Hit a 52 week high of 165.46 Closing the day 11/06/14 at 164.97 +0.39 +0.24% With a day low of 164.27 and a total volume of 448,126.
BCR Recent Posts: http://investorshangout.com/CR-Bard-BCR-50246/
BCR C.R. Bard Recent Headline News
Bard to Present at the Stifel Healthcare Conference
Business Wire - Wed Nov 05, 12:00PM CST
C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Stifel Healthcare Conference in New York City on November 19, 2014. Christopher S. Holland, senior vice president and chief financial officer, will discuss the company in a presentation scheduled to begin at 10:55 AM Eastern Standard Time.
BCR: 164.97 (+0.39)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.36 (+0.03), BCR: 164.97 (+0.39), INCY: 68.40 (+0.68), MYL: 53.50 (+0.03), AEGR: 21.98 (+1.66)
Covidien to Sell Stellarex DCB to Spectranetics for $30M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:07PM CST
Divesture of Covidien plc's (COV) Stellarex DCB is subject to the approval of the Federal Trade Commission and other regulatory agencies, as well as closure of the Medtronic-Covidien merger, which is slated to complete by early 2015.
BCR: 164.97 (+0.39), MDT: 68.74 (+0.04), GWPH: 74.38 (+3.04), COV: 92.60 (-0.72)
Insider Trading Alert - BCR, CYS And MMM Traded By Insiders
at The Street - Thu Oct 30, 9:45AM CDT
Stocks with insider trader activity include BCR, CYS and MMM
MMM: 156.05 (+0.36), BCR: 164.97 (+0.39), CYS: 8.87 (-0.04)
CR Bard Rises 1.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.97 (+0.39)
CR Bard Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.97 (+0.39)
CR Bard Beats Q3 Earnings and Revenues, '14 View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 7:50AM CDT
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $ 8.34-$8.38 from the prior range of $8.25-$8.35.
BCR: 164.97 (+0.39), CAH: 79.60 (+0.69), HSIC: 130.31 (+8.10), COO: 166.08 (+1.78)
Bard Announces Third Quarter Results
Business Wire - Wed Oct 22, 3:06PM CDT
C. R. Bard, Inc. (NYSE:BCR) today reported 2014 third quarter financial results. Third quarter 2014 net sales were $830.0 million, an increase of 9 percent over the prior-year period on both an as reported and constant currency basis.
BCR: 164.97 (+0.39)
Is CR Bard (BCR) Poised to Beat Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:36PM CDT
Our proven model does not conclusively show that CR Bard (BCR) is likely to beat earnings this quarter as it does not have the right combination of two key ingredients.
BCR: 164.97 (+0.39), ABAX: 53.84 (-0.61), EW: 123.57 (+2.47), HTWR: 76.66 (-0.68)
CR Bard's Lutonix 035: First FDA-Approved DCB in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 2:20PM CDT
The FDA approval for CR Bard's (BCR) Lutonix 035 DCB comes on the heels of a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in Jun 2014.
BCR: 164.97 (+0.39), CAH: 79.60 (+0.69), XRAY: 52.13 (+0.51), COO: 166.08 (+1.78)
The Lutonix(R) 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease
Business Wire - Fri Oct 10, 8:27AM CDT
C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix(R) 035 Drug Coated Balloon (DCB) Catheter for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in June 2014. The Lutonix(R) 035 DCB--the first and only FDA-approved DCB in the U.S.-- is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.
BCR: 164.97 (+0.39)
Bard's board sets dividend payment date of 31 October 2014
M2 - Thu Oct 09, 6:13AM CDT
The board of directors of C R Bard (NYSE:BCR), a medical company, Wednesday declared its quarterly dividend of USD0.22 per share on its common stock.
BCR: 164.97 (+0.39)
Bard Declares Quarterly Dividend
Business Wire - Wed Oct 08, 3:05PM CDT
The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today declared a regular quarterly dividend of 22 cents per share on Bard's common stock. The current indicated annual dividend rate is 88 cents per share. The dividend is payable on October 31, 2014 to shareholders of record at the close of business on October 20, 2014.
BCR: 164.97 (+0.39)
4 Stocks Spiking on Unusual Volume
at The Street - Tue Oct 07, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
BID: 39.10 (-0.17), BCR: 164.97 (+0.39), CLH: 46.56 (+1.57), MZOR: 10.93 (-0.23)
ISRG - Stunning Visualizations Pinpoint Hidden Risk
OptionVol - Mon Oct 06, 5:05PM CDT
This visualization is provided by: Capital Market Laboratories: Get Notified When CML Light Goes Live ISRG is trading $486.58, up 2.4% with IV30™ up 8.4%. The Symbol Summary is included below. Provided by Livevol Conclusion Relativ...
1 Comment
ISRG: 508.65 (+3.28), ABT: 43.69 (+0.03), BCR: 164.97 (+0.39), MDT: 68.74 (+0.04)
After Yesterday's Rally of 2.04% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 06, 4:24PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $147.04 to a high of $149.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $146.64 on volume of 804,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.97 (+0.39)
Global Temperature Management (Surface & Intravascular Systems- Warming & Cooling) Market Outlook 2019
M2 - Mon Oct 06, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p29rsk/temperature) has announced the addition of the "Temperature Management Market by Product , Application & by End User - Global Forecasts & Trends to 2019" report to their offering. The global temperature management market is estimated to grow at a CAGR of 2.4% from 2014 to 2019 A number of factors such as the worldwide development of technologically advanced temperature management systems, the increasing aging population (which in turn is increasing the demand for age-related surgeries), and growing prevalence of cancer and cardiovascular diseases are propelling the growth of the global market. However, unfavorable healthcare reforms in the U.S., product recalls, and rising price pressure on market players are some major factors restraining the growth of this market. In addition to this, the stringent regulatory policy in developed countries is a key challenge faced by market players in the market. On the basis of geography, this market is classified into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World. In 2014, the global temperature management market was dominated by North America. A number of factors such as the large volume of surgical procedures in North American countries, increasing number of surgical centers, high incidences of cardiac arrests and neurological disorders, and high adoption rate of technologically advanced devices in North American countries are driving the growth of the market in the North American region. The Asia-Pacific market is expected to grow at the highest CAGR from 2014 to 2019 due to factors such as large population base, increase in modernization of healthcare infrastructure, and rising government efforts to broaden public access for elective surgery. Agreements, partnerships, and joint ventures, and new product launches are the key strategies adopted by the major players to develop their position in the global market. Moreover, strategies such as expansions and strategic acquisitions were also adopted by a significant number of market players to strengthen their product portfolio and expand their geographic presence in the market. Report Scope Product - Surface & Intravascular Systems - Warming & Cooling Application - Acute & Perioperative Care - Delivery Suite End User - Surgeon & Anesthesiologist - Nursing & Paramedical Staff Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Temperature Management Market, By Product 8 Temperature Management Market, By Application 9 Temperature Management Market, By End User 10 Temperature Management Market, By Geography 11 Competitive Landscape 12 Company Profiles - 3M Company - C.R. Bard, Inc. - Cincinnati Sub-Zero Products, Inc. - Covidien PLC - Geratherm Medical AG - Inditherm PLC - Philips Healthcare (A Division of Koninklijke Philips N.V.) - Smiths Medical (A Division of Smiths Group PLC) - Stryker Corporation - Zoll Medical Corporation (Subsidiary of Asahi Kasei Corporation) For more information visit http://www.researchandmarkets.com/research/p2...emperature
MMM: 156.05 (+0.36), BCR: 164.97 (+0.39), SYK: 88.55 (+0.53)
Bard to Host Earnings Conference Call on October 22, 2014
Business Wire - Wed Oct 01, 10:00AM CDT
C. R. Bard, Inc. (NYSE:BCR) today announced that it will host a conference call on Wednesday, October 22, 2014 at 5:00 PM EDT, to discuss the company's third quarter 2014 operating results, and to provide financial guidance for the fourth quarter of 2014. Bard is scheduled to issue an earnings press release after the market closes on October 22, 2014.
BCR: 164.97 (+0.39)
CR Bard Improves on Strong Product Strategy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:35PM CDT
CR Bard (BCR) is well-diversified company, providing a complete line of products to treat medical conditions through less invasive procedures in a cost-effective manner.
MCK: 202.66 (+1.06), BCR: 164.97 (+0.39), COO: 166.08 (+1.78)
BCR Recent Posts: http://investorshangout.com/CR-Bard-BCR-50246/
BCR C.R. Bard Recent Headline News
Bard to Present at the Stifel Healthcare Conference
Business Wire - Wed Nov 05, 12:00PM CST
C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Stifel Healthcare Conference in New York City on November 19, 2014. Christopher S. Holland, senior vice president and chief financial officer, will discuss the company in a presentation scheduled to begin at 10:55 AM Eastern Standard Time.
BCR: 164.97 (+0.39)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.36 (+0.03), BCR: 164.97 (+0.39), INCY: 68.40 (+0.68), MYL: 53.50 (+0.03), AEGR: 21.98 (+1.66)
Covidien to Sell Stellarex DCB to Spectranetics for $30M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:07PM CST
Divesture of Covidien plc's (COV) Stellarex DCB is subject to the approval of the Federal Trade Commission and other regulatory agencies, as well as closure of the Medtronic-Covidien merger, which is slated to complete by early 2015.
BCR: 164.97 (+0.39), MDT: 68.74 (+0.04), GWPH: 74.38 (+3.04), COV: 92.60 (-0.72)
Insider Trading Alert - BCR, CYS And MMM Traded By Insiders
at The Street - Thu Oct 30, 9:45AM CDT
Stocks with insider trader activity include BCR, CYS and MMM
MMM: 156.05 (+0.36), BCR: 164.97 (+0.39), CYS: 8.87 (-0.04)
CR Bard Rises 1.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.97 (+0.39)
CR Bard Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.97 (+0.39)
CR Bard Beats Q3 Earnings and Revenues, '14 View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 7:50AM CDT
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $ 8.34-$8.38 from the prior range of $8.25-$8.35.
BCR: 164.97 (+0.39), CAH: 79.60 (+0.69), HSIC: 130.31 (+8.10), COO: 166.08 (+1.78)
Bard Announces Third Quarter Results
Business Wire - Wed Oct 22, 3:06PM CDT
C. R. Bard, Inc. (NYSE:BCR) today reported 2014 third quarter financial results. Third quarter 2014 net sales were $830.0 million, an increase of 9 percent over the prior-year period on both an as reported and constant currency basis.
BCR: 164.97 (+0.39)
Is CR Bard (BCR) Poised to Beat Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:36PM CDT
Our proven model does not conclusively show that CR Bard (BCR) is likely to beat earnings this quarter as it does not have the right combination of two key ingredients.
BCR: 164.97 (+0.39), ABAX: 53.84 (-0.61), EW: 123.57 (+2.47), HTWR: 76.66 (-0.68)
CR Bard's Lutonix 035: First FDA-Approved DCB in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 2:20PM CDT
The FDA approval for CR Bard's (BCR) Lutonix 035 DCB comes on the heels of a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in Jun 2014.
BCR: 164.97 (+0.39), CAH: 79.60 (+0.69), XRAY: 52.13 (+0.51), COO: 166.08 (+1.78)
The Lutonix(R) 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease
Business Wire - Fri Oct 10, 8:27AM CDT
C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix(R) 035 Drug Coated Balloon (DCB) Catheter for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in June 2014. The Lutonix(R) 035 DCB--the first and only FDA-approved DCB in the U.S.-- is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.
BCR: 164.97 (+0.39)
Bard's board sets dividend payment date of 31 October 2014
M2 - Thu Oct 09, 6:13AM CDT
The board of directors of C R Bard (NYSE:BCR), a medical company, Wednesday declared its quarterly dividend of USD0.22 per share on its common stock.
BCR: 164.97 (+0.39)
Bard Declares Quarterly Dividend
Business Wire - Wed Oct 08, 3:05PM CDT
The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today declared a regular quarterly dividend of 22 cents per share on Bard's common stock. The current indicated annual dividend rate is 88 cents per share. The dividend is payable on October 31, 2014 to shareholders of record at the close of business on October 20, 2014.
BCR: 164.97 (+0.39)
4 Stocks Spiking on Unusual Volume
at The Street - Tue Oct 07, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
BID: 39.10 (-0.17), BCR: 164.97 (+0.39), CLH: 46.56 (+1.57), MZOR: 10.93 (-0.23)
ISRG - Stunning Visualizations Pinpoint Hidden Risk
OptionVol - Mon Oct 06, 5:05PM CDT
This visualization is provided by: Capital Market Laboratories: Get Notified When CML Light Goes Live ISRG is trading $486.58, up 2.4% with IV30™ up 8.4%. The Symbol Summary is included below. Provided by Livevol Conclusion Relativ...
1 Comment
ISRG: 508.65 (+3.28), ABT: 43.69 (+0.03), BCR: 164.97 (+0.39), MDT: 68.74 (+0.04)
After Yesterday's Rally of 2.04% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 06, 4:24PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $147.04 to a high of $149.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $146.64 on volume of 804,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.97 (+0.39)
Global Temperature Management (Surface & Intravascular Systems- Warming & Cooling) Market Outlook 2019
M2 - Mon Oct 06, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p29rsk/temperature) has announced the addition of the "Temperature Management Market by Product , Application & by End User - Global Forecasts & Trends to 2019" report to their offering. The global temperature management market is estimated to grow at a CAGR of 2.4% from 2014 to 2019 A number of factors such as the worldwide development of technologically advanced temperature management systems, the increasing aging population (which in turn is increasing the demand for age-related surgeries), and growing prevalence of cancer and cardiovascular diseases are propelling the growth of the global market. However, unfavorable healthcare reforms in the U.S., product recalls, and rising price pressure on market players are some major factors restraining the growth of this market. In addition to this, the stringent regulatory policy in developed countries is a key challenge faced by market players in the market. On the basis of geography, this market is classified into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World. In 2014, the global temperature management market was dominated by North America. A number of factors such as the large volume of surgical procedures in North American countries, increasing number of surgical centers, high incidences of cardiac arrests and neurological disorders, and high adoption rate of technologically advanced devices in North American countries are driving the growth of the market in the North American region. The Asia-Pacific market is expected to grow at the highest CAGR from 2014 to 2019 due to factors such as large population base, increase in modernization of healthcare infrastructure, and rising government efforts to broaden public access for elective surgery. Agreements, partnerships, and joint ventures, and new product launches are the key strategies adopted by the major players to develop their position in the global market. Moreover, strategies such as expansions and strategic acquisitions were also adopted by a significant number of market players to strengthen their product portfolio and expand their geographic presence in the market. Report Scope Product - Surface & Intravascular Systems - Warming & Cooling Application - Acute & Perioperative Care - Delivery Suite End User - Surgeon & Anesthesiologist - Nursing & Paramedical Staff Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Temperature Management Market, By Product 8 Temperature Management Market, By Application 9 Temperature Management Market, By End User 10 Temperature Management Market, By Geography 11 Competitive Landscape 12 Company Profiles - 3M Company - C.R. Bard, Inc. - Cincinnati Sub-Zero Products, Inc. - Covidien PLC - Geratherm Medical AG - Inditherm PLC - Philips Healthcare (A Division of Koninklijke Philips N.V.) - Smiths Medical (A Division of Smiths Group PLC) - Stryker Corporation - Zoll Medical Corporation (Subsidiary of Asahi Kasei Corporation) For more information visit http://www.researchandmarkets.com/research/p2...emperature
MMM: 156.05 (+0.36), BCR: 164.97 (+0.39), SYK: 88.55 (+0.53)
Bard to Host Earnings Conference Call on October 22, 2014
Business Wire - Wed Oct 01, 10:00AM CDT
C. R. Bard, Inc. (NYSE:BCR) today announced that it will host a conference call on Wednesday, October 22, 2014 at 5:00 PM EDT, to discuss the company's third quarter 2014 operating results, and to provide financial guidance for the fourth quarter of 2014. Bard is scheduled to issue an earnings press release after the market closes on October 22, 2014.
BCR: 164.97 (+0.39)
CR Bard Improves on Strong Product Strategy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:35PM CDT
CR Bard (BCR) is well-diversified company, providing a complete line of products to treat medical conditions through less invasive procedures in a cost-effective manner.
MCK: 202.66 (+1.06), BCR: 164.97 (+0.39), COO: 166.08 (+1.78)
